1026839-76-8

Basic information

• Product Name: (5-{3-[4-(5-dimethylcarbamoyl-4-methyl-thiazol-2-yl)-2-propyl-phenoxy]-propoxy}-indan-1-yl)-acetic acid ethyl ester
• Synonyms: (5-{3-[4-(5-dimethylcarbamoyl-4-methyl-thiazol-2-yl)-2-propyl-phenoxy]-propoxy}-indan-1-yl)-acetic acid ethyl ester
• CAS NO: 1026839-76-8
• Molecular Weight: 564.746
• Mol File: 1026839-76-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (5-{3-[4-(5-dimethylcarbamoyl-4-methyl-thiazol-2-yl)-2-propyl-phenoxy]-propoxy}-indan-1-yl)-acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5-{3-[4-(5-dimethylcarbamoyl-4-methyl-thiazol-2-yl)-2-propyl-phenoxy]-propoxy}-indan-1-yl)-acetic acid ethyl ester(1026839-76-8)
• EPA Substance Registry System: (5-{3-[4-(5-dimethylcarbamoyl-4-methyl-thiazol-2-yl)-2-propyl-phenoxy]-propoxy}-indan-1-yl)-acetic acid ethyl ester(1026839-76-8)

Safety Data

• Hazardous Substances Data: 1026839-76-8(Hazardous Substances Data)

Upstream product

• 162713-88-4 ethyl (5-methoxy-2,3-dihydro-1H-inden-1-yl)ethanoate 
• 767-00-0 4-cyanophenol 
• 90923-69-6 3-allyl-4-hydroxy-benzonitrile 
• 21779-34-0 ethyl 2-[(1E)-5-methoxy-2,3-dihydro-1H-inden-1-ylidene]acetate 
• 33148-47-9 4-allyloxy-benzonitrile 
• 5111-70-6 5-methoxy-1-indanone 
• 724467-23-6 {5-[3-(4-cyano-2-propyl-phenoxy)-propoxy]-indan-1-yl}-acetic acid ethyl ester 
• 724466-33-5 ethyl [(1S)-5-(3-bromopropoxy)-2,3-dihydro-1H-inden-1-yl]acetate 
• 496061-80-4 ethyl [(1S)-5-hydroxy-2,3-dihydro-1H-inden-1-yl]acetate 
• 496061-79-1 ethyl [(1S)-5-methoxy-2,3-dihydro-1H-inden-1-yl]acetate 
• 496061-78-0 [(1S)-5-methoxy-2,3-dihydro-1H-inden-1-yl]acetic acid 
• 105211-77-6 4-hydroxy-3-propylbenzonitrile 
• 724467-24-7 ethyl ((1S)-5-{3-[4-(aminocarbonothioyl)-2-propylphenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl)acetic acid 

Relevant articles and documents

Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α/γ/δ pan agonists: Synthesis, structure-activity relationship, and in vivo efficacy

Compounds that simultaneously activate the three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, gamma, and delta hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic sy